Novo Holdings adds two life science business leaders to its advisory group

Novo Holdings adds two life science business leaders to its advisory group

Date
October 24, 2018
Location
Copenhagen

Novo Holdings A/S is very pleased to announce the appointment of Cees de Jong, former CEO of Chr. Hansen, and Jean-Luc Bélingard, Vice-President of Institut Mérieux, as new members of its advisory group, the Novo Advisory Group.

Cees de Jong was until recently CEO of Chr. Hansen, a successful global supplier of bioscience-based ingredients to the food, health and animal feed industries. Under Cees de Jong’s five-year leadership, sales of Chr. Hansen increased from €719 million (USD 829 million) to €1.083 billion (USD 1.249 billion), and the company’s market capitalisation increased from €3.4 billion (USD 3.9 billion) to more than €10 billion (USD 11.5 billion). Novo Holdings owns 25.7% of the shares of Chr. Hansen.

Jean-Luc Bélingard has spent 28 years in the pharmaceutical industry. He is Vice-President of Institut Mérieux, a French holding company that controls three life science companies and employs more than 17,000 people. His previous positions include Chairman and CEO of bioMérieux S.A., a world leading diagnostics company, and Chairman and CEO of the Ipsen Group, a leading biopharmaceutical group. In addition, he holds several board memberships, including at Lupin Ltd, a Mumbai-based global pharmaceuticals company, and at LabCorp, a US-based diagnostic and drug development services company. He is also Foreign Trade Advisor to the Government of France.

Kasim Kutay, CEO of Novo Holdings, says: “I am very pleased that Cees de Jong and Jean-Luc Bélingard are joining the Novo Advisory Group. They both have highly impressive track records in the life sciences, and their insights and knowledge will be of great value to Novo Holdings. In particular, given our investments in and commitment to the diagnostics and bioindustrial sectors, Cees and Jean-Luc will add very important capabilities to the Novo Advisory Group.”

Novo Holdings is the holding company of the Novo Group, with total assets of €48 billion (USD 55 billion) as of year-end 2017. Novo Holdings is wholly owned by the Novo Nordisk Foundation and currently wholly or partly owns more than 80 life-science companies, primarily in Europe and the United States.

The Novo Advisory Group is a life science expert panel that supports the investment activities of the Principal Investments team of Novo Holdings.

Cees de Jong says: “As CEO of Chr. Hansen I experienced first hand the qualities of Novo Holdings as a life science focused long-term investor. I am delighted to be joining the Novo Advisory Group and, in particular, I look forward to assisting Novo Holdings with their bioindustrial investment activities.”

Jean-Luc Bélingard says: “Having spent my entire career in the pharmaceutical and diagnostic sectors, I have long admired the commitment to innovation and success of the Novo Group companies. I am excited to be joining such a distinguished group as the Novo Advisory Group.”

 

About Cees de Jong

Born in the Netherlands

2013–2018

President and CEO, Chr. Hansen

2007–2011

COO and member of the Board, Crucell

2003–2007

Group Vice President, Quest International

2000–2002

Business Group Director, Campina

1989–2000

Business Group Director, Gist-Brocades and DSM

 Selected board appointments 

2018-

Chairman, Supervisory Board, Mediq

2017-

Chairman, Supervisory Board, ForFarmers N.V.

2012–2013

Chairman, Supervisory Board, Polyganics BV

2012–2013

Member, Advisory Board, Roland Berger Strategy Consultants

2011–2016

Member, Supervisory Board, Protein Sciences Corporation

2007–2010

Chairman, Supervisory Board, GreenChem BV

Education

1989

MBA, Rotterdam School of Management,
Erasmus University Rotterdam, Netherlands

1987

MD, Erasmus University Rotterdam, Netherlands

 

About Jean-Luc Bélingard

Born in France

2018-

Vice-President, Institut Mérieux

2014–2017

Chairman, bioMérieux S.A.

2011–2014

Chairman and CEO, bioMérieux S.A.

2002–2010

Chairman and CEO, Ipsen Group

1999-2001

CEO, bioMérieux-Pierre Fabre

1974–1998

Positions at various companies,
including F. Hoffmann–La Roche and Merck, Sharpe and Dohme

Selected other board memberships and other appointments

2016-

Chairman, FEFIS (French Federation of Health Industries)

2015-

Board member, Lupin Ltd

2014-

Member, Bill & Melinda Gates Foundation CEO Roundtable

2013-

Board member, Laboratoire Pierre Fabre

2011-

Board member, Stallergenes SA

2006-2009

Board member, Institut National de la Santé et
de la Recherche Médicale (INSERM)

1995-

Board member, Laboratory Corporation of America

Education

1974

MBA, Cornell University

1971

BA, École des Hautes Études Commerciales de Paris

 

Further information

Christian Mostrup Scheel, Senior Press Officer, Novo Nordisk Foundation
phone: +45 3067 4805, cims@novo.dk

Novo Holdings uses cookies to ensure that we give you the best experience on our website. Read more